Skip to main content
Google Tag Manager
P&T COMMUNITY
Register
Sign in
Search form
Search
News
Approvals, Launches, & New Indications
Pipeline Plus
Research News
Industry Trends
Safety Issues
Agency Actions
Health Care Reform
Guidelines
Clinical Trials
P&T
Current issue
Past issues
Contact us
Digital Edition
Subscribe
P&T TV
Dr. David B. Nash
Meeting Reports
Health Care & Law
Drug Forecast
More
Meeting Highlights
Medication Errors
Prescription: Washington
Authors
About
Contact Us
News
P&T Journal
Formulary Kits
INGREZZA®
(valbenazine) tablets
JAKAFI®
ruxolitinib (tablets)
KEDRAB™
(Rabies Immune Globulin [Human])
LOKELMA™
(sodium zirconium cyclosilicate) 10 g for oral suspension
PERSERIS™
(risperidone) for extended-release injectable suspension
ZULRESSO™
(brexanolone) injection CIV
You are here
Home
News by month %2 2018
News by month August 2018
PTCommunity News August 2018
Better Access to Diabetes Drugs for Medicaid Beneficiaries Under ACA
CMS Tightens Oversight of Medicaid Demonstration Project Costs
How Can Medicare Save A Billion Bucks? Use Generics
FDA Approves First Drug for Neurotrophic Keratitis
Seventeen Companies Stop Sales of E-Liquids with Kid-Friendly Advertising
Around the Country, States Pass Bills to Curb Drug Costs
FDA Permits Marketing of Transcranial Magnetic Stimulation for Treatment of Obsessive Compulsive Disorder
FDA Approves First Generic Version of EpiPen
DOJ and DEA Propose Lowering Opioid Production Quotas by 10% in 2019
Predicting the Risk for Five Deadly Diseases
FDA Approves Galafold for Fabry Disease in Adults
New Targeted RNA-based Infusion to Treat Rare Polyneuropathy in Adults
New Vaginal Ring Approved for An Entire Year of Birth Control
Women Are Ten Times More Likely to Get Tested for BRCA1 and BRCA2
FDA Takes Steps to Encourage Development of Opioid Addiction Drugs
Increased Risk of Cancer Relapse with Long-term Use of Azithromycin
Disappointing Results for Some Workplace Wellness Programs
Havrix Now Approved For Use in Children Aged 12 Months and Older
Phase 3 Trial of Telbivudine Reaches Efficacy Endpoint
